Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

Lewis, Penney; Marsden, Paul; Gee, Tony; Nunan, T. O.; Malsey, M; Griffin, Steven; Dussek, J E

doi:10.1016/s0140-6736(94)90753-6

Cited by 202 publications

(57 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most patients with NSGCT mature teratoma was found in the residual mass (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). In five of them (16)(17)(18)(19)(20) FDG uptake was found (SUV 1.7-3.7).…”

Section: Resultsmentioning

confidence: 99%

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Spermon¹,

et al. 2002

View full text Add to dashboard Cite

Objective To investigate the role of 18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET) tumorous residual mass the FDG-PET scan was clearly positive; in four of 12 with mature teratoma and inflammation components retroperitoneally, the FDG-PET was also positive. In contrast, eight patients with solitary mature teratoma had a negative PET result. In four of five patients with necrosis after chemotherapy the PET result was correctly negative. All eight patients on surveillance had a negative PET scan and were free of disease at median (range) of 14 (8-18) months. Interestingly, of the 12 patients with a correct negative PET result, 11 had no mature teratoma in their primary tumour. Nine of 10 patients with SGCT were correctly staged. Two FDG-PET studies showed increased uptake; in one, a viable seminomatous mass was found and in the other there was inflammation in the residual mass. In all other patients the FDG-PET scan correctly predicted absence of viability in the residual mass. Conclusions In primary staging, FDG-PET has no benefit over CT. In re-staging, a negative FDG-PET result predicts fibrotic residual mass in seminomatous GCT. Moreover, it could be useful to predict fibrotic residual mass in NSGCT in those patients with no teratoma component in their primary tumour.

show abstract

Section: Resultsmentioning

confidence: 99%

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Spermon¹,

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Most investigators have used focal techniques and concentrated on mediastinal lymph node staging [5][6][7][8][9]. Concerning the detection of distant metastases by whole-body FDG PET, three studies have already been published showing that the technique has excellent accuracy [10][11][12]. However, in these studies, there were no data comparing the sensitivity and specificity of PET and of the reference imaging modality for the detection of metastasis site by site.…”

Section: Discussionmentioning

confidence: 99%

“…This uptake can be used in PET studies to visualize the tumour with high contrast compared with the surrounding tissue [2][3][4]. Considerable experience is now available on the diagnostic value of FDG PET in the mediastinal staging of lung cancer [5][6][7][8][9] but analysis of the efficiency of FDG PET for the detection of distant metastasis remains fragmentary [10][11][12]. This paper reports our current clinical experience in 110 patients with nonsmall cell lung cancer (NSCLC).…”

Section: Introductionmentioning

confidence: 99%

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

Bury

Barreto

Daenen

et al. 1998

European Journal of Nuclear Medicine and Molecular Imaging

281

View full text Add to dashboard Cite

Abstract. Despite advances in morphological imaging, some patients with lung cancer are found to have non resectable disease at surgery or die of recurrence within a year of surgery. At present, metastatic bone involvement is usually assessed using bone scintigraphy, which has a high sensitivity but a poor specificity. We have attempted to evaluate the utility of the fluorine-18 deoxyglucose positron emission tomography (FDG PET) for the detection of bone metastasis. One hundred and ten consecutive patients with histological diagnosis of non-small cell lung cancer (NSCLC) who underwent both FDG PET and bone scintigraphy were selected for this review. In this group, there were 43 patients with metastatic disease (stage IV). Among these, 21 (19% of total group) had one or several bone metastases confirmed by biopsy (n = 8) or radiographic techniques (n = 13). Radionuclide bone scanning correctly identified 54 out of 89 cases without osseous involvement and 19 out of 21 osseous involvements. On the other hand, FDG PET correctly identified the absence of osseous involvement in 87 out of 89 patients and the presence of bone metastasis in 19 out of 21 patients. Thus using PET there were two false-negative and two false-positive cases. PET and bone scanning had, respectively, an accuracy of 96% and 66% in the evaluation of osseous involvement in patients with NSCLC. In conclusion, our data suggest that whole-body FDG PET may be useful in detecting bone metastases in patients with known NSCLC.

show abstract

“…In a study of 50 patients where PET and CT findings were reported jointly, the sensitivity rose to 93%, specificity 97% and accuracy 96% in the detection of mediastinal nodal disease [63]. PET has been shown to detect occult extrathoracic metastases in 11-14% of patients selected for curative resection and alter management in up to 40% of cases [66][67][68].…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Diagnostic imaging of lung cancer

Hollings¹,

Shaw²

2002

Eur Respir J

120

View full text Add to dashboard Cite

Carcinoma of the bronchus is the most common malignancy in the Western world. It is also the leading cause of cancer-related death accounting for 32% of all cancer deaths in males and 25% in females [1]. In the USA it causes more deaths than cancers of the colon, breast and prostate combined [2]. Disappointingly, in a recent UK survey of improvements in cancer survival [3], carcinoma of the bronchus showed the smallest percentage reduction in the number of deaths avoided between 1981-1990 (0.2%). This compares badly with breast (11% reduction) and melanoma (32%). The overall 5-yr survival for lung cancer diagnosed between 1986-1990 was only 5.3% (against 66% for breast and 76% for melanoma). It is on this background that the radiologist remains actively employed in the detection, diagnosis, staging and review of this common malignancy.

show abstract

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

Cited by 202 publications

References 7 publications

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

Diagnostic imaging of lung cancer

Contact Info

Product

Resources

About

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

Cited by 202 publications

References 7 publications

The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

Diagnostic imaging of lung cancer

Contact Info

Product

Resources

About

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours